Acetylcysteine 10%, 20% · oral solution
Dry Eye/OSD
Approved uses
Adjuvant therapy for abnormal, viscid, or inspissated mucous secretions in acute and chronic bronchopulmonary disease, pulmonary complications of cystic fibrosis, and tracheostomy care
Nebulized 3 to 5 mL of the 20% solution or 6 to 10 mL of the 10% solution 3 to 4 times daily (range 1 to 10 mL of the 20% or 2 to 20 mL of the 10% every 2 to 6 hours); by direct instillation, 1 to 2 mL of a 10% or 20% solution as often as every hour, or every 1 to 4 hours into a tracheostomy
Acetaminophen overdose, to prevent or lessen hepatic injury
140 mg/kg PO loading dose diluted to 5% with a diet soft drink; if the predetoxification plasma acetaminophen level is clearly in the toxic range or could not be obtained, a 70 mg/kg maintenance dose 4 hours later, repeated at 4-hour intervals for a total of 17 doses; start within 24 hours of ingestion
OFF-LABELNot in the FDA label for this product
Filamentary keratitis, refractory
Compounded topical solution 5% to 10% QID, the most commonly reported ocular regimen; the cited case report used 10%
Case report · uncontrolled
Weak and uncontrolled. A single case report of recurrent filamentary keratitis refractory to lubricants, punctal plugs, steroids, and lid hygiene showed complete filament resolution and symptom relief sustained at 10 months on a compounded 10% solution given with preservative-free ointment and oral doxycycline, and a systematic review of 106 ocular studies found 5% to 10% four times daily the most common regimen with rare corneal necrosis at higher concentrations.
Mucus fishing syndrome
Compounded 5% topical solution. The two-case report states no frequency; the commonly reported ocular regimen for this drug is 5% to 10% QID.
2 case reports · confounded
Very weak. Two case reports used topical 5% inside a multimodal regimen of topical corticosteroid, lid hygiene, and low-level light therapy, and the authors state the contribution of the light therapy cannot be determined from these findings alone, and the acetylcysteine contribution is likewise unisolated.
Contraindications
- Hypersensitivity to acetylcysteine.
- None for oral use in acetaminophen overdose.
Solution for inhalation or oral administration, 10% (100 mg/mL) and 20% (200 mg/mL), 30 mL vials
The sulfhydryl group probably opens disulfide linkages in mucus, lowering viscosity; mucolytic activity is unaltered by DNA and increases with increasing pH, with significant mucolysis between pH 7 and 9. Applied topically it thins and loosens adherent corneal mucus filaments, with reviews also crediting hydroxyl radical scavenging and modulation of inflammatory cascades on the ocular surface.
Warnings & Precautions
- Not for injection: Acetylcysteine solution is for inhalation (mucolytic agent) or oral administration (acetaminophen antidote) and is not approved for parenteral injection; no ophthalmic route or dose appears on this label. The linked label covers inhalation and oral use only, so every ocular application is off-label.
- Contamination: This product does not contain an antimicrobial agent, and care must be taken to minimize contamination of the sterile solution; refrigerate the remainder of an opened vial and use within 96 hours.
- Color change: A light purple color in the opened vial is the result of a chemical reaction that, per the label, does not have a significant effect on safety or mucolytic effectiveness.
- Increased concentration in the nebulizer: Continued nebulization with a dry gas concentrates the drug through evaporation of the solvent, and extreme concentration may impede nebulization and efficient delivery; dilute with Sterile Water for Injection as concentration occurs.
- Incompatibility: Drug stability and safety of acetylcysteine when mixed with other drugs in a nebulizer have not been established, and it should not be mixed with certain antibiotics, such as tetracycline hydrochloride, oxytetracycline hydrochloride, and erythromycin lactobionate.
- Bronchospasm: Asthmatics require close observation; most cases are relieved quickly by a nebulized bronchodilator, and progression warrants immediate discontinuation.
- Increased volume of liquified bronchial secretions: This may occur after proper administration; when cough is inadequate, maintain the open airway by mechanical suction if necessary, and clear a mechanical block due to foreign body or local accumulation by endotracheal aspiration, with or without bronchoscopy.
- Generalized urticaria: Reported rarely with oral use for acetaminophen overdose; discontinue unless treatment is essential and the allergic symptoms can be otherwise controlled.
- Encephalopathy due to hepatic failure: If it becomes evident, discontinue acetylcysteine to avoid further administration of nitrogenous substances; there are no data indicating that acetylcysteine adversely influences hepatic failure, but this remains a theoretical possibility.
- Aggravated vomiting and upper gastrointestinal hemorrhage: Oral acetylcysteine may aggravate the severe and persistent vomiting that occasionally occurs in acute acetaminophen overdose, and dilution minimizes this. Evaluate patients at risk of gastric hemorrhage (e.g., esophageal varices, peptic ulcers) for the risk of upper gastrointestinal hemorrhage versus the risk of developing hepatic toxicity.
Common Side Effects
Corneal necrosis is rare and has been reported at higher topical concentrations; this label lists no ocular adverse effects. In mucolytic use, adverse effects have included stomatitis, nausea, vomiting, fever, rhinorrhea, drowsiness, clamminess, chest tightness, and bronchoconstriction; clinically overt bronchospasm occurs infrequently and unpredictably, even in patients with asthmatic bronchitis. Oral use, especially in the large doses needed to treat acetaminophen overdose, may result in nausea, vomiting, and other gastrointestinal symptoms; rash with or without mild fever has been observed rarely. Acquired sensitization has been reported rarely and has not been confirmed by patch testing in patients; it has been confirmed in several inhalation therapists who reported dermal eruptions after frequent and extended exposure.
Pregnancy: Rat and rabbit reproduction studies at doses up to 2.6 times the human dose showed no teratogenicity and no evidence of impaired fertility or harm to the fetus; there are no adequate and well-controlled studies in pregnant women. Because animal reproduction studies may not always be predictive of human responses, use during pregnancy only if clearly needed.
Lactation: It is not known whether acetylcysteine is excreted in human milk; exercise caution when giving it to a nursing woman.
No pediatric use section on this label. For acetaminophen overdose in patients weighing less than 20 kg (usually patients younger than 6 years), calculate the dose: 140 mg/kg loading dose, 70 mg/kg maintenance dose.